|
1.
|
Kshatriya S, Lui K, Salah A, Szombathy T,
Freeman RH, Reams GP, Spear RM and Villarreal D: Obesity
hypertension: the regulatory role of leptin. Int J Hypertens.
2011:2706242011. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Lönnqvist F: The obese (ob) gene
and its product leptin - a new route toward obesity treatment in
man? QJ Med. 89:327–332. 1996.PubMed/NCBI
|
|
3.
|
Misra A and Garg A: Leptin, its receptor
and obesity. J Investig Med. 44:540–548. 1996.PubMed/NCBI
|
|
4.
|
Tartaglia LA, Dembski M, Weng X, Deng N,
Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J,
et al: Identification and expression cloning of a leptin receptor,
OB-R. Cell. 83:1263–1271. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Esler M, Vaz M, Collier G, Nester P,
Jennings G, Kaye D, Seals D and Lambert G: Leptin in human plasma
is derived in part from the brain, and cleared by the kidneys.
Lancet. 351:879–880. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Eikelis N, Lambert G, Wiesner G, Kaye D,
Schlaich M, Morris M, Hastings J, Socratous F and Esler M:
Extra-adipocyte leptin release in human obesity and its relation to
sympathoadrenal function. Am J Physiol Endocrinol Metab.
286:E774–E752. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Morash B, Li A, Murphy PR, Wilkinson M and
Ur E: Leptin gene expression in the brain and pituitary gland.
Endocrinology. 140:5995–5998. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Considine RV, Sinha MK, Heiman ML,
Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee
LJ, Bauer TL and Caro JF: Serum immunoreactive-leptin
concentrations in normal-weight and obese humans. New Engl J Med.
334:292–295. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Garrison RJ, Kannel WB, Stokes J III and
Castelli WP: Incidence and precursors of hypertension in young
adults: the Framingham Offspring Study. Prev Med. 16:235–251. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wofford MR and Hall JE: Pathophysiology
and treatment of obesity hypertension. Curr Pharm Des.
10:3621–3637. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Shek EW, Brands MW and Hall JE: Chronic
leptin infusion increases arterial pressure. Hypertension.
31:409–414. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim
SZ, Park BH and Kim SH: Leptin reduces plasma ANP level via nitric
oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol.
298:R1007–R1016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Huang F, Xiong X, Wang H, You S and Zeng
H: Leptin-induced vascular smooth muscle cell proliferation via
regulating cell cycle, activating ERK1/2 and NF-kappaB. Acta
Biochim Biophys Sin (Shanghai). 42:325–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Sengenès C, Berlan M, De Glisezinski I,
Lafontan M and Galitzky J: Natriuretic peptides: a new lipolytic
pathway in human adipocytes. FASEB J. 14:1345–1351. 2000.
|
|
15.
|
Sengenès C, Bouloumie A, Hauner H, Berlan
M, Busse R, Lafontan M and Galitzky J: Involvement of a
cGMP-dependent pathway in the natriuretic peptide-mediated
hormone-sensitive lipase phosphorylation in human adipocytes. J
Biol Chem. 278:48617–48626. 2003.PubMed/NCBI
|
|
16.
|
Moro CC, Galitzky J, Sengenès C, Crampes
F, Lafontan M and Berlan M: Functional and pharmacological
characterization of the natriuretic peptide-dependent lipolytic
pathway in human fat cells. J Pharmacol Exp Ther. 308:984–992.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Uehlinger DE, Weidemann P, Gnädinger MP,
Hasler L, Bachmann C, Shaw S, Hellmüller B and Lang RE: Increase in
circulating insulin induced by atrial natriuretic peptide in normal
humans. J Cardiovasc Pharmacol. 8:1122–1129. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Galitzky J, Sengenès C, Thalamus C,
Marques MA, Senard JM, Lafontan M and Berlan M: The
lipid-mobilizing effect of atrial natriuretic peptide is unrelated
to sympathetic nervous system activation or obesity in young men. J
Lipid Res. 42:536–544. 2001.
|
|
19.
|
Birkenfeld AL, Boschmann M, Moro C, Adams
F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M and Jordan J:
Lipid mobilization with physiological atrial natriuretic peptide
concentrations in humans. J Clin Endocrinol Metab. 90:3622–3628.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Vesely DL: Natriuretic hormones. Seldin
and Giebisch’s, The Kidney: Physiology and Pathophysiology. Alpern
RJ, Moe OW and Caplan M: 5th edition. Elsevier/North - Holland
Biomedical Press; Amsterdam: pp. 1241–1281. 2013
|
|
21.
|
Martin DR, Pevahouse JB, Trigg DJ, Vesely
DL and Buerket JE: Three peptides from the ANF prohormone
NH2-terminus are natriuretic and/or kaliuretic. Am J
Physiol. 258:F1401–F1408. 1990.PubMed/NCBI
|
|
22.
|
Gunning ME, Brady HR, Otuechere G, Brenner
BM and Ziedel ML: Atrial natriuretic peptide(31–67) inhibits
Na+ transport in rabbit inner medullary collecting duct
cells. Role of prostaglandin E2. J Clin Invest. 89:1411–1417.
1992.
|
|
23.
|
Benjamin BA and Peterson TV: Effects of
proANF-(31–67) on sodium excretion in conscious monkeys. Am J
Physiol. 269:R1351–R1355. 1995.
|
|
24.
|
Zeidel ML: Regulation of collecting duct
Na+ reabsorption by ANP 31-67. Clin Exp Pharmacol
Physiol. 22:121–124. 1995. View Article : Google Scholar
|
|
25.
|
Villarreal D, Reams GP, Taraben A and
Freeman RH: Hemodynamic and renal effects of proANF31-67 in
hypertensive rats. Proc Soc Exp Biol Med. 221:166–170. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Dietz JR, Scott DY, Landon CS and Nazian
SJ: Evidence supporting a physiological role for proANP-(1–30) in
the regulation of renal excretion. Am J Physiol Regul Integr Comp
Physiol. 280:R1510–R1517. 2001.PubMed/NCBI
|
|
27.
|
Vesely DL, Douglass MA, Dietz JR, Gower WR
Jr, McCormick MT, Rodriguez-Paz G and Schocken DD: Three peptides
from the atrial natriuretic factor prohormone amino terminus lower
blood pressure and produce diuresis, natriuresis and/or kaliuresis
in humans. Circulation. 90:1129–1140. 1994. View Article : Google Scholar
|
|
28.
|
Vesely DL, Douglass MA, Dietz JR, Giordano
AT, McCormick MT, Rodriguez-Paz G and Schocken DD: Negative
feedback of atrial natriuretic peptides. J Clin Endocrinol Metab.
78:1128–1134. 1994.PubMed/NCBI
|
|
29.
|
Vesely DL, Dietz JR, Parks JR, Baig M,
McCormick MT, Cintron G and Schocken DD: Vessel dilator enhances
sodium and water excretion and has beneficial hemodynamic effects
in persons with congestive heart failure. Circulation. 98:323–329.
1998. View Article : Google Scholar
|
|
30.
|
Sugarawa A, Nakao K, Sakamoto M, Morii N,
Yamada T, Itoh H, Shiono S and Imura H: Plasma concentration of
atrial natriuretic polypeptide in essential hypertension. Lancet.
2:1426–1427. 1985. View Article : Google Scholar
|
|
31.
|
Arendt R, Gerbes A, Ritter D, Stangl E and
Zähringer J: Atrial natriuretic factors in plasma of patients with
arterial hypertension, heart failure or cirrhosis of the liver. J
Hypertens Suppl. 4:S131–S135. 1986.PubMed/NCBI
|
|
32.
|
McMurray RW Jr and Vesely DL: Weight
reduction decreases atrial natriuretic factor and blood pressure in
obese patients. Metabolism. 38:1231–1237. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
McMurray RW Jr and Vesely DL: Weight
reduction decreases the circulating concentration of the N-terminus
of the ANF prohormone. Am J Med Sci. 303:2–8. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
McMurray RW Jr and Vesely DL:
Calorie-restricted weight reduction, blood pressure, and atrial
natriuretic peptides. Nutrition. 9:178–182. 1993.PubMed/NCBI
|
|
35.
|
Cao R, Brakenhielm E, Wahlestedt C,
Thyberg J and Cao Y: Leptin induces vascular permeability and
synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc
Natl Acad Sci USA. 98:6390–6395. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Nguyen JP, Frost CD, Lane ML, Skelton lv
WP, Skelton M and Vesely DL: Novel dual inhibitors of vascular
endothelial growth factor and VEGFR2 receptor. Eur J Clin Invest.
42:1061–1067. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Fain JN, Kanu A, Bahouth SW, Gowan GS and
Lloyd Hiler M: Inhibition of leptin release by atrial natriuretic
peptide (ANP) in human adipocytes. Biochem Pharmacol. 65:1883–1888.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Sarzani R, Dessì-Fulgheri P, Paci VM,
Espinosa E and Rappelli A: Expression of natriuretic peptide
receptors in human adipose and other tissues. J Endocrinol Invest.
19:581–585. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Vesely DL: Peptides from the N-terminus of
the atrial natriuretic factor prohormone enhance guanylate cyclase
activity and increase cyclic GMP levels in a wide variety of
tissues. Mol Cell Biochem. 109:43–50. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Jensen MD, Haymond MW, Rizza RA, Cryer PE
and Miles JM: Influence of body fat distribution on free fatty acid
metabolism in obesity. J Clin Invest. 80:1168–1173. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Bougnères P, Stunff CL, Pecqueur C,
Pinglier E, Adnot P and Ricquier D: In vivo resistance of lipolysis
to epinephrine. A new feature of childhood onset obesity. J Clin
Invest. 99:2568–2573. 1997.PubMed/NCBI
|
